Sulfadoxine
Sulfadoxine is a long-acting sulfonamide antibiotic used in combination with pyrimethamine (Fansidar) for the treatment and prevention of malaria caused by susceptible Plasmodium falciparum strains, particularly for intermittent preventive treatment in pregnancy and in malaria-endemic regions. The combination exploits sequential blockade of the folate synthesis pathway: sulfadoxine inhibits dihydropteroate synthase while pyrimethamine inhibits dihydrofolate reductase, providing synergistic antiparasitic activity. Resistance has limited its use in some geographic areas.
Khối lượng phân tử
310,3300 g/mol
LogP
0,70
TPSA
125,00 Ų
Lipinski RO5
Đạt
Lĩnh vực điều trị
Cơ chế tác dụng
Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.
Cấu trúc 2D
Cite this structure
Embed this structure
SMILES
COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC
InChI
InChI=1S/C12H14N4O4S/c1-19-10-11(14-7-15-12(10)20-2)16-21(17,18)9-5-3-8(13)4-6-9/h3-7H,13H2,1-2H3,(H,14,15,16)
Molecular Formula
C12H14N4O4S
HBD / HBA
2 / 8
Liên kết có thể quay
5
Nguyên tử nặng
21
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Câu hỏi thường gặp
Sulfadoxine is a long-acting sulfonamide antibiotic used in combination with pyrimethamine (Fansidar) for the treatment and prevention of malaria caused by susceptible Plasmodium falciparum strains, particularly for intermittent preventive treatment in pregnancy and in malaria-endemic regions. The combination exploits sequential blockade of the folate synthesis pathway: sulfadoxine inhibits dihydropteroate synthase while pyrimethamine inhibits dihydrofolate reductase, providing synergistic antiparasitic activity. Resistance has limited its use in some geographic areas.
Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.
Yes, Sulfadoxine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1539. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 17134. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="sulfadoxine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/sulfadoxine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/sulfadoxine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/sulfadoxine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="sulfadoxine"></drugfyi-drug>